AUROPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.0
| Stock Code | AUROPHARMA | Market Cap | 73,548 Cr. | Current Price | 1,268 ₹ | High / Low | 1,320 ₹ |
| Stock P/E | 34.3 | Book Value | 369 ₹ | Dividend Yield | 0.32 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,211 ₹ | DMA 200 | 1,176 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | 0.06 % | PAT Qtr | 595 Cr. | PAT Prev Qtr | 581 Cr. |
| RSI | 58.3 | MACD | 29.4 | Volume | 17,33,270 | Avg Vol 1Wk | 15,46,588 |
| Low price | 994 ₹ | High price | 1,320 ₹ | PEG Ratio | 8.04 | Debt to equity | 0.21 |
| 52w Index | 84.0 % | Qtr Profit Var | 26.0 % | EPS | 36.7 ₹ | Industry PE | 27.6 |
📈 Chart & Trend Analysis: AUROPHARMA is trading above both its 50 DMA (1,211 ₹) and 200 DMA (1,176 ₹), with the current price at 1,268 ₹. This indicates a bullish undertone supported by moving averages.
📊 Momentum Indicators: RSI at 58.3 shows healthy momentum, leaning bullish but not overbought. MACD at 29.4 confirms bullish crossover, signaling short-term strength.
📉 Bollinger Bands & Volume: Price is near the upper band, suggesting strong buying interest. Current volume (17,33,270) is above weekly average (15,46,588), confirming active participation and momentum-driven rally.
🔑 Support & Resistance Zones:
- Support: 1,210 ₹ (50 DMA), 1,176 ₹ (200 DMA), 994 ₹ (major low)
- Resistance: 1,300–1,320 ₹ (recent highs)
Optimal Entry: 1,210–1,240 ₹ (near DMA support)
Optimal Exit: 1,300–1,320 ₹ (resistance zone)
📌 Trend Status: The stock is trending upward with strong momentum and bullish confirmation from indicators.
Positive
- EPS of 36.7 ₹ supports valuation strength.
- Quarterly PAT improved to 595 Cr. from 581 Cr., showing earnings growth.
- Strong trading volumes confirm investor interest.
Limitation
- ROCE (10.8%) and ROE (8.65%) are modest compared to peers.
- PEG ratio (8.04) indicates expensive growth relative to earnings.
- Debt-to-equity ratio at 0.21 shows moderate leverage compared to debt-free peers.
Company Negative News
- FII holding decreased (-0.26%), showing slight reduction in foreign investor confidence.
Company Positive News
- DII holding increased (+0.06%), reflecting domestic institutional support.
- Quarterly profit variation (+26.0%) indicates strong earnings momentum.
Industry
- Industry PE at 27.6 is lower than AUROPHARMA’s PE (34.3), suggesting premium valuation.
- Pharma sector outlook remains favorable with consistent demand and export opportunities.
Conclusion
🚀 AUROPHARMA is in a bullish trend, trading above key moving averages with positive MACD and strong volume support. Fundamentals show improving profits, though ROE/ROCE remain modest and valuations are stretched. Traders may consider entry near 1,210–1,240 ₹ with exits around 1,300–1,320 ₹. Momentum is positive, making it suitable for short-term trades, but cautious position sizing is advised due to premium valuation.
Would you like me to extend this into a peer benchmarking overlay comparing AUROPHARMA against other pharma sector stocks (valuation, ROE/ROCE, momentum) so you can see relative strength before deciding entry?